Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 23;7(5):230-234.
doi: 10.9740/mhc.2017.09.230. eCollection 2017 Sep.

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature

Katie T B Touma  1 , Daniel C Touma  2
Affiliations

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature

Katie T B Touma et al. Ment Health Clin. .

Abstract

Introduction: Pimavanserin (Nuplazid™) is an atypical antipsychotic currently indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. The antipsychotic effects of this new agent are believed to occur via selective inverse agonist activity at serotonin 5-HT2a receptors.

Methods: Study authors completed a literature review of 2 published randomized controlled trials of pimavanserin for the treatment of Parkinson disease psychosis. The Food and Drug Administration Briefing Document by the Psychopharmacologic Drugs Advisory Committee for the review of pimavanserin dated March 29, 2016, was reviewed for additional information on 2 unpublished trials.

Results: Pimavanserin has demonstrated no worsening of motor symptoms of Parkinson disease, but only 1 of 4 trials has shown consistent statistically significant improvements in psychotic symptoms compared with placebo.

Discussion: Options for the treatment of Parkinson disease psychosis are limited. The selective receptor profile of pimavanserin offers advantages for tolerability. Further studies are warranted to better provide clinicians and patients with information regarding the clinical utility of this agent.

Keywords: Parkinson disease; Pimavanserin; psychosis.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors have nothing to disclose in terms of financial conflict of interest.

References

    1. Nuplazid (pimavanserin) [prescribing information]. San Diego (CA): Acadia Pharmaceuticals Inc; April 2016.
    1. Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. . On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res. 2014; 39 10: 2008- 17. DOI: 10.1007/s11064-014-1293-3. PubMed PMID: 24682754. - DOI - PMC - PubMed
    1. Zahodne LB, Fernandez HH. . Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging. 2008; 25 8: 665- 82. PubMed PMID: 18665659. - PMC - PubMed
    1. Thanvi BR, Lo TC, Harsh DP. . Psychosis in Parkinson's disease. Postgrad Med J. 2005; 81 960: 644- 6. DOI: 10.1136/pgmj.2004.032029. PubMed PMID: 16210460. - DOI - PMC - PubMed
    1. Weiner DM, Vanover KE, Brann MR, Meltzer HY, Davis RE. . Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. Curr Opin Investig Drugs. 2003; 4 7: 815- 9. PubMed PMID: 14619402. - PubMed